| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 483.33% | HC Wainwright & Co. | → $3.5 | Reiterates | Buy → Buy |
| 11/06/2023 | 483.33% | HC Wainwright & Co. | $2 → $3.5 | Maintains | Buy |
| 08/24/2023 | 233.33% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 08/14/2023 | 233.33% | HC Wainwright & Co. | $7 → $2 | Maintains | Buy |
| 08/09/2023 | 233.33% | Maxim Group | $12 → $2 | Maintains | Buy |
| 05/12/2023 | 1066.67% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/24/2023 | 900% | HC Wainwright & Co. | $10 → $6 | Reiterates | → Buy |
| 02/09/2023 | 1900% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 02/08/2023 | 1566.67% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/08/2023 | 19733.33% | Ladenburg Thalmann | → $119 | Reiterates | → Buy |
| 08/25/2022 | 983.33% | Ladenburg Thalmann | → $6.5 | Initiates Coverage On | → Buy |
| 08/15/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/11/2022 | 316.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 04/19/2022 | 400% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 01/19/2022 | 316.67% | Maxim Group | → $2.5 | Initiates Coverage On | → Buy |
What is the target price for Kiora Pharmaceuticals (KPRX)?
The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.50 expecting KPRX to rise to within 12 months (a possible 483.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiora Pharmaceuticals (KPRX)?
The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Kiora Pharmaceuticals (KPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Kiora Pharmaceuticals (KPRX) correct?
While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $3.50. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.60, which is within the analyst's predicted range.